AskAt received an Official Decision of Grant dated November 19, 2021 of a use patent for its EP4 receptor antagonist in the treatment of NASH-associated liver cancer. The notice was issued by the Russian Federal Service for Intellectual Property, Patents and Trademarks (Rospatent), in connection with Russian Patent Application No. 2020109376 (Filing Date: November 2, 2017). In addition to Russia, the use patent has been granted in Canada, China, Europe, Japan, Mexico, and the U.S.